How to Standardize Audit Risks and Legal Exposure Management Across Global Markets

The pharmaceutical industry is heavily regulated, particularly concerning controlled substances. This has necessitated a robust framework for audit risks and legal exposure management. In this explainer manual, we will dissect relevant regulations, provide documentation best practices, and discuss common deficiencies to help regulatory affairs professionals navigate these complexities globally, with a specific focus on the US, UK, and EU markets.

Context

Audit risks and legal exposure management form a critical aspect of regulatory compliance in the pharmaceutical sector. Controlled substances, regulated under various frameworks, require careful handling and meticulous documentation. The potential for legal liabilities and regulatory actions underscores the need for a standardized approach across global markets.

Legal/Regulatory Basis

The legal landscape for controlled substances is shaped by several key regulations and guidelines:

• US Regulations: In the United States, controlled substances are regulated under the Controlled Substances Act (CSA) and its implementing regulations found in Title 21 of the Code of Federal Regulations (CFR). The Drug Enforcement Administration (DEA) administers this act, overseeing the handling and distribution of controlled substances.
• EU Regulations: The European Union follows the EU Directive 2001/83/EC and Regulation (EC) No. 726/2004, which establish a harmonized framework for the approval and management of medicinal products, including controlled substances.
• UK Regulations: In the UK, the Misuse of Drugs Act 1971 regulates controlled substances along with associated regulations under the Medicines Act 1968 and the Controlled Drugs (Supervision of Management and Use) Regulations 2013.

Additionally, the FDA, EMA, and MHRA provide additional guidance on compliance expectations pertaining to controlled substances.

Documentation

Documentation is the backbone of effective audit risk management and legal exposure mitigation. The following types of documentation are crucial:

Licensing and Registration Documents

Maintain current registrations with the relevant authorities, including DEA registrations in the US, EMA licenses in the EU, and MHRA registrations in the UK. Ensure that all licenses for handling controlled substances are consistently renewed and accessible for audit purposes.

SOPs and Training Records

Standard Operating Procedures (SOPs) should be developed and implemented to outline best practices for handling controlled substances. Additionally, documentation of training sessions and employee understanding of these SOPs is vital.

Batch Records and Product Specifications

Accurate batch records provide critical information regarding the manufacturing and control processes. Document all specifications, including the raw materials used, processes followed, and any deviations from standard procedures.

Audit Reports and CAPA Documentation

Maintain comprehensive audit reports and Corrective Actions and Preventive Actions (CAPA) documentation. Be prepared to provide details on any findings, actions taken, and follow-up assessments.

Review/Approval Flow

The flow for the review and approval of controlled substances requires careful coordination among multiple teams. The following steps provide a structured approach:

1. Pre-Submission Preparation: Ensure that all necessary documentation is in place. Engage with CMC teams to align submissions with regulatory requirements.
2. Initial Review: Conduct an internal review involving Quality Assurance (QA), Clinical, and Regulatory Affairs (RA) teams to confirm that all documentation meets regulatory expectations.
3. Submission: Submit documentation to the relevant agencies, ensuring adherence to timelines specified by FDA, EMA, or MHRA.
4. Agency Review: Monitor the submission for feedback from regulatory agencies. Be prepared to respond to questions or deficiencies raised during the review process.
5. Post-Approval Monitoring: Once approved, establish protocols for routine monitoring and ensure continuous compliance with regulatory requirements.

Common Deficiencies

Awareness of common deficiencies can greatly enhance compliance with controlled substances regulations. Here are typical issues faced by companies:

Incomplete Documentation

One of the most frequent deficiencies noted during inspections is incomplete or poorly organized documentation. Proper documentation is essential for defending against legal exposure, and establishing a centralized documentation system can mitigate this risk.

Inadequate Training

Failure to train staff comprehensively on compliance with controlled substances regulations can lead to significant issues. Regular training sessions, along with documented evaluations, are necessary to ensure operational understanding.

Poor Audit Trails

Audit trails must be clear and maintain integrity throughout the product lifecycle. Any discrepancies in audit trails can raise suspicions and lead to regulatory penalties.

Delayed Responses to Agency Queries

Timeliness is crucial when responding to agency questions during the review process. Delays in response can lead to approval delays or worse, extended scrutiny from agencies.

RA-Specific Decision Points

Understanding specific decision points in the regulatory process is critical for effective compliance:

Variation vs. New Application

Companies must determine whether a proposed change qualifies as a variation or requires a new application. Variations typically involve minor changes that do not significantly affect the quality, safety, or efficacy of the product. Common examples include changes to the manufacturing process or updates to labeling that do not alter the product’s use.

Justifying Bridging Data

When submitting data from studies conducted in different geographic regions, justification for bridging data may be necessary. Companies must provide a clear scientific rationale demonstrating how findings from one population can be extrapolated to another. Consideration should be given to genetic, environmental, and cultural factors that may influence efficacy or safety profiles.

Appropriate Classification of Controlled Substances

Ensuring the correct classification of a product as a controlled substance is paramount. Companies must assess the chemical structure and proposed uses thoroughly to avoid non-compliance. If there is any uncertainty, consulting with legal and regulatory experts early in the development process is advisable.

Practical Tips for Compliance

To effectively manage audit risks and legal exposure, implement the following practical tips:

• Establish a Compliance Framework: Create a compliance framework that encompasses all aspects of handling controlled substances, from development to distribution.
• Engage Stakeholders: Regularly involve stakeholders from various departments (e.g., CMC, QA, Clinical) to ensure that compliance measures are integrated across functions.
• Conduct Regular Audits: Plan internal audits to identify potential risks and areas for improvement prior to external audits by regulatory agencies.
• Utilize Technology: Leverage technology to enhance documentation and compliance tracking. Electronic systems can streamline documentation processes and improve data integrity.

Ultimately, a proactive and organized approach to audit risks and legal exposure management will significantly enhance compliance with controlled substances regulations across multiple jurisdictions.